Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01498874 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

A Phase 2 study of Acne Vulgaris, sponsored by Xoma (US).

Completed
Registry status
Phase 2
Development phase
127
Enrollment target
19
Study locations

NCT01498874 is a Phase 2 study of Acne Vulgaris that has completed, run by Xoma (US). The registered enrollment target is 127 participants, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (53% lower). The trial reports 19 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01498874, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Xoma (US).

COMPLETED
Registry status
Phase 2
Development phase
127 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.

Conditions Studied

Acne Vulgaris

Interventions

  • DRUG Placebo
  • DRUG gevokizumab

Study Locations (19)

North Carolina

  • - Charlotte
  • - High Point
  • - Raleigh

Texas

  • - Arlington
  • - Austin
  • - Houston

California

  • - Riverside
  • - San Diego

Arkansas

  • - Hot Springs

Colorado

  • - Denver

Connecticut

  • - New Haven

Michigan

  • - Bay City

Minnesota

  • - Fridley

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2011-12
Est. Completion 2013-06
Phase Phase 2

Sponsor

Xoma (US)

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01498874

The ClinicalTrials.gov registry entry for NCT01498874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 273-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (53% lower). The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01498874 reports 19 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, Texas, California.

Frequently Asked Questions

What is clinical trial NCT01498874 about?

NCT01498874 is a clinical study titled "Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris". The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.

What is the current status of trial NCT01498874?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2011-12. Estimated completion is 2013-06.

What conditions does trial NCT01498874 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT01498874?

The interventions under investigation include: Placebo (DRUG), gevokizumab (DRUG).

Who is sponsoring clinical trial NCT01498874?

This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01498874 being conducted?

This trial has 19 study locations across Arkansas, California, Colorado, Connecticut, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acne Vulgaris

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.